Literature DB >> 9705355

Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist.

M J Lee1, S Thangada, C H Liu, B D Thompson, T Hla.   

Abstract

EDG-1, an inducible G-protein-coupled receptor from vascular endothelial cells, is a high affinity receptor for sphingosine 1-phosphate (SPP) (Lee, M-J., van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998) Science 279, 1552-1555). In this study, we show that lysophosphatidic acid (LPA), a platelet-derived bioactive lipid structurally related to SPP, is an agonist for EDG-1. LPA binds to EDG-1 receptor with an apparent Kd of 2.3 microM. In addition, LPA binding to EDG-1 induces receptor phosphorylation, mitogen-activated protein kinase activation, as well as Rho-dependent morphogenesis and P-cadherin expression. These data suggest that LPA is a low-affinity agonist for EDG-1. Activation of the endothelial receptor EDG-1 by platelet-derived lipids LPA and SPP may be important in thrombosis and angiogenesis, conditions in which critical platelet-endothelial interactions occur.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705355     DOI: 10.1074/jbc.273.34.22105

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Lysophosphatidic acid-mediated Ca2+ mobilization in human SH-SY5Y neuroblastoma cells is independent of phosphoinositide signalling, but dependent on sphingosine kinase activation.

Authors:  K W Young; R A Challiss; S R Nahorski; J J MacKrill
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

5.  Ceramide 1-phosphate increases intracellular free calcium concentrations in thyroid FRTL-5 cells: evidence for an effect mediated by inositol 1,4,5-trisphosphate and intracellular sphingosine 1-phosphate.

Authors:  Susanna Högback; Petra Leppimäki; Britt Rudnäs; Sonja Björklund; J Peter Slotte; Kid Törnquist
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

6.  Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway.

Authors:  Xianjun Fang; Shuangxing Yu; Janos L Tanyi; Yiling Lu; James R Woodgett; Gordon B Mills
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 7.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8.

Authors:  Yasuyuki Kihara; Michael Maceyka; Sarah Spiegel; Jerold Chun
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

8.  Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.

Authors:  Xin Qin; Zhichao Yue; Baonan Sun; Wenzhong Yang; Jia Xie; Eric Ni; Yi Feng; Rafat Mahmood; Yanhui Zhang; Lixia Yue
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1.

Authors:  C H Liu; S Thangada; M J Lee; J R Van Brocklyn; S Spiegel; T Hla
Journal:  Mol Biol Cell       Date:  1999-04       Impact factor: 4.138

Review 10.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.